Advanced prostate cancer

Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in...


The Food and Drug Administration ( FDA ) has approved the first oral gonadotropin-releasing hormone ( GnRH ) receptor antagonist,...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide (...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets,...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...


Prostate cancer growth and progression may be linked to neurogenesis and to medical anti- Parkinson treatment, but results are inconclusive....


Recent guidelines recommend against routine screening for prostate cancer, partly because of the risks associated with overtreatment of clinically indolent...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a...


The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many...


The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment...